SARS-CoV-2 can trigger brain inflammation and deterioration. Dipyridamole may offer an effective treatment strategy.

Key Messages

Dipyridamole (also known as Curantil) can inhibit acute inflammation and the progression of fibrosis through its anti-inflammatory activities.

Dipyridamole is especially useful among COVID-19 patients who demonstrate early increases in the pro-clotting protein, D-dimer.

Dipyridamole slows and reduces brain inflammation through its antioxidant and endothelial-protective activities. This makes dipyridamole suitable as a candidate to prevent both early and late-stage brain inflammation (neuroinflammation) seen in some COVID-19 patients.

Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova

Publication Date: September 14, 2020
Peer Reviewed: Yes
Publication Type: Original | Theoretical

SARS-CoV-2 (COVID-19) as a Predictor of Neuroinflammation and Neurodegeneration: Potential Treatment Strategies

M.V. Putilina, D.V. Grishin


The SARS-CoV-2 (COVID-19) pandemic has attracted attention to the challenge of neuroinflammation as an unavoidable component of viral infections. Acute neuroinflammatory responses include activation of resident tissue macrophages in the CNS followed by release of a variety of cytokines and chemokines associated with activation of oxidative stress and delayed neuron damage. This makes the search for treatments with indirect anti-inflammatory properties relevant. From this point of view, attention is focused on further study of the treatment of patients with COVID-19 with dipyridamole (Curantil) which, having antiviral and anti-inflammatory effects, can inhibit acute inflammatory activity and progression of fibrosis, is a drug with potential, especially among patients with early increases in the D-dimer concentration and severe signs of microangiopathy.